期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 21, 期 1, 页码 291-301出版社
IOS PRESS
DOI: 10.3233/JAD-2010-091501
关键词
Alzheimer's disease; amyloid; biomarkers; non-Alzheimer's disease dementia; plasma
资金
- University of Antwerp
- Stichting Alzheimer Onderzoek
- Thomas Riellaerts Research Fund
- Institute Born-Bunge
The objective of this study was to evaluate the diagnostic performance of full-length and N-truncated plasma amyloid-beta (A beta) forms in patients with Alzheimer's disease (AD) and non-Alzheimer's disease dementia (non-AD) as compared to healthy control subjects. Plasma samples from 50 AD, 50 non-AD, and 47 control subjects were included and analyzed using a multiparameter fluorimetric bead-based immunoassay for the simultaneous quantification of different A beta forms. No significant differences in A beta isoforms were detected between dementia and controls; or AD, non-AD, and controls. Compared to control subjects, pooled dementia patients (AD and non-AD) and AD patients alone had significantly lower plasma A beta(1-42)/A beta(N-42) ratios. In each diagnostic group, all plasma A beta concentrations were significantly correlated. No significant correlations between plasma A beta forms and age were found. The low diagnostic performance of cross-sectional plasma A beta measurements hampers future application as diagnostic markers or screening tools for dementia. CSF biomarker analysis remains superior, although the possible application of longitudinal plasma A beta measurements as screening tools for dementia remains to be elucidated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据